BrainStorm Cell Therapeutics Inc. Updates on Financial Results and Corporate Developments

In a recent announcement, BrainStorm Cell Therapeutics Inc., a biotechnology company based in New York, has rescheduled its first quarter 2025 financial results release to post-market close on May 15, 2025. The company, listed on the Nasdaq under the ticker BCLI, is a pioneer in developing autologous adult stem cell therapies aimed at treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson’s disease (PD).

The financial results, initially planned for a different date, will now be discussed in detail during an investor conference call scheduled for Monday, May 19, 2025, at 8:30 a.m. Eastern Time. This call will feature a corporate update from Chaim Lebovits, President and Chief Executive Officer, alongside key executives including Haro Hartounian, Ph.D., Chief Operating Officer; Bob Dagher, M.D., Chief Medical Officer; and Alla Patlis, CPA, MBA, Interim Chief Financial Officer.

Key Developments in NurOwn® Program

A significant focus of the upcoming discussions will be the progress of BrainStorm’s NurOwn® development program. NurOwn, a stem cell therapy for ALS, is at the forefront of the company’s efforts. Chaim Lebovits emphasized the company’s commitment to initiating a Phase 3b trial, which aims to confirm the therapy’s efficacy in early-stage ALS patients. This trial is crucial for supporting a new Biologics License Application (BLA).

The company has recently submitted an amendment to its Investigational New Drug (IND) application, incorporating updated documentation essential for regulatory compliance and trial integrity. This step is part of a broader strategy to finalize clinical trial agreements with leading academic centers and complete necessary preparations for trial execution and manufacturing.

Community and Investor Engagement

BrainStorm continues to receive strong support from the ALS community, which is vital for the company’s ongoing research and development efforts. The upcoming investor call will provide an opportunity for stakeholders to engage directly with the company’s leadership, ask questions, and gain insights into the strategic direction and operational progress.

Participants interested in joining the call can access it via the provided toll-free and international numbers or through the webcast link. For those unable to attend, a replay of the conference call will be available, ensuring that all interested parties have the opportunity to stay informed about BrainStorm’s developments.

As BrainStorm Cell Therapeutics Inc. navigates the complexities of bringing innovative therapies to market, its focus remains on advancing treatments that could significantly impact the lives of patients with neurodegenerative diseases. The company’s efforts in the NurOwn® program underscore its commitment to this mission, with the potential to offer a valuable treatment option for ALS patients if approved.